Search

BackgroundThe course of novel coronavirus disease 2019 (COVID-19) has been of special concern in patients with inflammatory rheumatic diseases (IRDs) due to the immune dysregulation that may be associated with these diseases and the medications used for IRDs, that may affect innate immune responses.ObjectiveIn this cohort study, we aimed to report the disease characteristics and variables associated with COVID-19 outcome among Turkish patients with IRDs.MethodsBetween April and June, 2020, 167 adult IRD patients with COVID-19 were registered from 31 centers in 14 cities in Turkey. Disease outcome was classified in 4 categories; (i) outpatient management, (ii) hospitalization without oxygen requirement, (iii) hospitalization with oxygen requirement, and (iv) intensive care unit (ICU) admission or death. Multivariable ordinal logistic regression analysis was conducted to determine variables associated with a worse outcome.Results165 patients (mean age: 50 ± 15.6 years, 58.2% female) were included. Twenty-four patients (14.5%) recovered under outpatient management, 141 (85.5%) were hospitalized, 49 (30%) required inpatient oxygen support, 22 (13%) were treated in the ICU (17 received invasive mechanic ventilation) and 16 (10%) died. Glucocorticoid use (OR: 4.53, 95%CI 1.65-12.76), chronic kidney disease (OR: 12.8, 95%CI 2.25-103.5), pulmonary disease (OR: 2.66, 95%CI 1.08-6.61) and obesity (OR: 3.7, 95%CI 1.01-13.87) were associated with a worse outcome. Biologic disease-modifying antirheumatic drugs (DMARDs) do not seem to affect COVID-19 outcome while conventional synthetic DMARDs may have a protective effect (OR: 0.36, 95%CI 0.17-0.75). Estimates for the associations between IRD diagnoses and outcome were inconclusive.ConclusionsAmong IRD patients with COVID-19, comorbidities and glucocorticoid use were associated with a worse outcome, while biologic DMARDs do not seem to be associated with a worse outcome.

Giriş: Ailevi Akdeniz ateşi (AAA) en sık görülen herediter, oto-inflamatuar hastalıktır. Bu çalışmada amacımız AAA hastalarında cinsiyet ve klinik bulgular, hastalık şiddeti ve tedavi uyumu arasındaki ilişkiyi incelemektir. Materyal ve Metot: AAA tanılı 150 hastanın arşiv dosyaları retrospektif olarak incelendi. Hastalık şiddeti uluslararası AAA şiddet skorlama sistemi (ISSF) ile, tedavi uyumları 6 maddeli modifiye Morisky ölçeği ile değerlendirildi ve cinsiyetler arası kıyaslandı. Bulgular: AAA tanılı 150 hastanın 87’si (%58) kadın ve 63’ü (%42) erkekti. Erezipel benzeri eritem (EBE) kadınlarda (%51,70 ve %19, p= 0,03) ve miyalji erkeklerde daha sıktı (% 31 ve % 36,50, p=0,015). Diğer klinik bulgular cinsiyetler arası farklılık göstermedi. ISSF skorları arasında da farklılık saptanmadı (2,93±2,05 ve 3,12±2,2; p=0,716). Tedavi uyumu ve bilgi düzeyleri her iki grupta benzerdi. (sırasıyla p=0,228 ve p=0,112,). Sonuç: AAA hastalarında klinik bulgular, ISSF skorları, tedavi uyumu cinsiyetler arası farklılık göstermemektedir. AAA hastalarında cinsiyetin prognoz üzerine etkisi yoktur.